Aldehyde Compounds for Pulmonary Fibrosis via Hemoglobin Oxygen Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) and related conditions such as hypoxia and autoimmune diseases are limited, with no effective drugs available to address oxygen deprivation and associated organ damage.
Innovation Solution
Development of aldehyde compounds like (S)-2-hydroxy-6-((1-nicotinoylpiperidin-2-yl)methoxy)benzaldehyde that increase hemoglobin oxygen affinity, improving oxygen uptake and delivery to tissues, thereby treating hypoxemia and pulmonary fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-fibrotic drugs (pirfenidone and nintedanib) are used for IPF treatment, then fibrosis progression is slowed, but treatment options remain limited and oxygen deprivation is not effectively addressed
Solution Approach 1:
The patent changes the chemical structure parameters by developing novel aldehyde compounds with specific molecular configurations (Formula 1 and Formula 2) that differ from existing anti-fibrotic drugs. These structural parameter changes enable new mechanisms of action that simultaneously address fibrosis and improve oxygen binding, expanding treatment versatility while maintaining efficacy
Solution Approach 2:
The invention creates compounds that perform multiple functions: they inhibit fibrosis progression like existing drugs while simultaneously increasing hemoglobin oxygen affinity. This multi-functionality resolves the contradiction by providing a single treatment option that addresses both fibrosis and hypoxemia, thereby expanding therapeutic versatility without requiring multiple separate medications
2Quantity of substance
If hemoglobin oxygen affinity is increased to improve oxygen uptake, then oxygen delivery to tissues is enhanced, but oxygen release to tissues may be compromised
Solution Approach 1:
The patent applies local quality by creating compounds that bind to specific local sites on hemoglobin (the N-terminal valine of the alpha chain) to form Schiff bases. This localized binding modifies oxygen affinity properties at the molecular level, enabling enhanced oxygen uptake in the lungs while the body's natural physiological conditions (pH, CO2 levels) regulate oxygen release at the tissues, thus resolving the contradiction between uptake and delivery
3Adaptability or versatility
If new aldehyde compounds are developed to treat multiple conditions, then therapeutic versatility is improved, but drug development complexity increases
Solution Approach 1:
The patent manages complexity by systematically varying specific parameters in the molecular structure (substituents at defined positions in Formula 1 and Formula 2) rather than creating entirely novel complex structures. This parameter-based approach allows exploration of multiple therapeutic applications while maintaining a manageable level of structural complexity and enabling systematic optimization
Solution Approach 2:
The invention achieves versatility through a unified mechanism: the aldehyde group in all compounds binds to hemoglobin to increase oxygen affinity, providing a common therapeutic effect across different conditions (IPF, hypoxia, autoimmune diseases). This universal mechanism reduces development complexity compared to creating condition-specific drugs, as one core structure can address multiple indications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds significantly improve hypoxemia, attenuate pulmonary inflammation and fibrosis, and enhance oxygen delivery to tissues, offering a therapeutic benefit for IPF and related conditions.
Implementation Method 1
it is believed that reference Compound 1 binds covalently and reversibly via Schiff base to the N-terminal valine of the hemoglobin (Hb) alpha chain
Implementation Method 2
reference Compound 1 allosterically modulates the Hb-oxygen (Hb-O2) affinity. Without being bound by any theory, it also believed that reference Compound 1 elicits a concentration-dependent left shift in the oxygen equilibrium curve with subsequent increase in Hb-O2 affinity and arterial oxygen loading
Data Source
Figure 1A
Figure 1B~1C
Figure 1D
AI summary
This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.